Le Lézard
Classified in: Health, Science and technology, Business
Subjects: PDT, CXP

Sekisui Diagnostics Opens $1.9 Million Bioprocess Innovation Centre

BURLINGTON, Massachusetts, Nov. 25, 2019 /PRNewswire/ -- Sekisui Diagnostics' Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK. The new R&D facility, costing $1.9 million, is part of a long-term investment strategy to grow its share of the Microbial Biopharma CDMO market, with future investment expected to focus on expanding its cGMP manufacturing capabilities, starting with additional ISO 8 clean room capacity coming online by the end of 2019.

BioProcess Innovation Centre

The new Bioprocess Innovation Centre includes 250m2 of laboratory space and 134m2 of office space, more than doubling its R&D laboratory space to facilitate Process Transfer and Development.

The new facility includes dedicated and separate microbial fermentation development, protein purification, analysis and molecular biology laboratories.

Sekisui's Biopharma CDMO service offering, BioProduction by Sekisui, is focused on expression and purification from microbial fermentation. Building on over 40 years' experience in this field, the group's expertise lies in the production of enzymes, however its capabilities are also suitable for plasmids, antibody fragments, and other protein production.

"This investment represents our commitment to serve our customers with innovative process development solutions," said Will Stockburn, Sekisui Diagnostics (UK) Ltd.'s General Manager. "Over many years we have built a technical competency in enzyme production process development. The new facility will enable our team to attract more customers as the Biopharma CDMO market grows."

About Sekisui Diagnostics

Sekisui Diagnostics is a global company committed to improving patient's lives by providing innovative medical diagnostics to physicians and laboratories through a global commercial network.  Product lines include clinical chemistry and coagulation systems, reagents, rapid test kits, point-of-care systems. The Enzyme business forms part of this group and, in addition to BioProduction by Sekisui, offers a broad portfolio of Diagnostic enzymes and critical raw materials.


Sekisui Diagnostics Logo

Photo - https://mma.prnewswire.com/media/1033976/BioProcess.jpg 
Logo - https://mma.prnewswire.com/media/412597/sekisui_diagnostics_logo.jpg

These press releases may also interest you

at 02:05
The Healthcare Information and Management Systems Society (HIMSS) and Elsevier, the global information analytics business specializing in science and health, are proud to announce the call for submissions for the Annual HIMSS-Elsevier Digital...

at 01:05
Regulatory News: Lysogene (Paris:LYS) (FR0013233475 ? LYS) today announced its corporate agenda* for 2020: 17 February 2020: Sales and cash position at the end of 2019 20 March 2020: 2019 annual results 22 April 2020: First...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of...

at 01:05
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia...

at 01:04
CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient in Australia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib,...

23 jan 2020
Sasakawa Health Foundation has announced the start of its first-ever social media campaign with organizations of persons affected by leprosy. Taking part are 17 people's organizations in 16 countries that are linking up...

News published on 25 november 2019 at 08:00 and distributed by: